Biotech Values

[apljack]

TTPH-This may be the reason for the value rise. The article was published today, but I'm sure the local investment community has known about this news.

These 5 Mass. biotechs are getting $12M to fight ‘superbugs’

A Boston-based accelerator program that funds the development of potential life-saving antibacterial drugs has awarded more than $12 million to five local biotechs.

The public-private partnership, called Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator — or CARB-X — said Thursday that it will invest $24 million in 11 drug and diagnostic companies, five of which are based in Massachusetts, and could make up to an additional $24 million in milestone payments.

(You have to view the slide show to see each of the 5 featured co's, but to cut to the chase, TTPH is getting $4 million over the next 18 months without any apparent dilution. The investment is the single biggest one for the 5 companies listed, indicating some robust confidence.)

http://www.bizjournals.com/boston/news/2017/03/31/these-5-mass-biotechs-are-getting-12m-to-fight.html?ana=yahoo&yptr=yahoo

A little more detail on TP-6076, which is the candidate that this grant will support:

About TP-6076
TP-6076 is a novel, synthetic, fluorocycline antibiotic candidate generated through Tetraphase’s proprietary chemistry technology. It has demonstrated potent in vitro activity against multidrug-resistant bacteria including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii. As part of an ongoing phase 1 clinical development program, Tetraphase has evaluated intravenous TP-6076 in a phase 1 single-ascending dose clinical trial and is planning to initiate a phase 1 multiple-ascending dose clinical trial in 2017.

https://finance.yahoo.com/news/tetraphase-pharmaceuticals-tp-6076-selected-200100771.html